From: Hurdles to breakthrough in CAR T cell therapy of solid tumors
Cancer | Study type | Target locus | Tool | CAR | Reference |
---|---|---|---|---|---|
Liver cancer | In vitro | TGFβRII | CRISPR/Cas9 | Mesothelin | [179] |
Ovarian cancer | In vivo | ||||
Leukemia | In vivo | TRAC | CRISPR/Cas9 | CD19 | [187] |
Leukemia | In vitro | TRAC | TALEN | CD19 | |
In vivo | |||||
Myeloma | In vitro | CD20 | TALEN | BCMA | [190] |
In vivo | |||||
Leukemia | In vitro | GM-CSF | CRISPR/Cas9 | CD19 | [178] |
In vivo | |||||
Leukemia | In vitro | TRAC | CRISPR/Cas9 | CD7 | [191] |
In vivo | |||||
Lymphoma | In vitro | TRAC | TALEN | CD22 | [192] |
In vivo | PD-1 | ||||
Leukemia | In vitro | TRAC | CRISPR/Cas9 | CD22 | [193] |
PD-1 | |||||
Leukemia | In vitro | TRAC | TALEN | CD3 | [194] |
In vivo | |||||
Leukemia | In vitro | TRAC | TALEN | CD20 | [195] |
PD-1 | |||||
Leukemia | In vivo | LAG-3 | CRISPR/Cas9 | CD19 | [135] |
Prostate cancer | In vivo | TRAC | CRISPR/Cas9 | PSCA | [134] |
B2M | |||||
PD1 | |||||
Lymphoma | In vitro | GM-CSF | TALEN | CD22 | [196] |
Glioma | In vitro | PD-1 | CRISPR/Cas9 | EGFRvIII | [197] |
Glioma | In vitro | PD-1 | CRISPR/Cas9 | CD133 | [198] |
In vivo | |||||
Leukemia | In vitro | TRAC | ZFN | CD19 | [199] |
Glioma | In vitro | DGK | CRISPR/Cas9 | EGFRvIII | [200] |
In vivo | |||||
Prostate cancer | In vivo | TRAC | CRISPR/Cas9 | PSCA | [134] |
B2M | |||||
PD1 | |||||
Leukemia | In vitro | TRAC | CRISPR/Cas9 | BCMA | [174] |
CD10 |